PURPOSE: We examined the presence of the p53 and Bcl-2 oncoproteins, as detected by immunohistochemistry, in muscle-invasive bladder cancer and correlated this with survival. MATERIALS AND METHODS: Formalin-fixed cystectomy specimens from 41 consecutive patients with mean follow-up of 52 months were used. Five patients were either lost to follow-up or died of other diseases and were not included in the survival evaluation. RESULTS: Eighteen of 36 patients died of metastatic transitional cell carcinoma. p53 immunostaining was found in 61% of patients. In 21 of 23 this staining was homogeneous, with more than 75% of cancer cells staining using a DO-1/DO-7 antibody cocktail. p53 staining was not correlated with stage (p>0.25) or grade (p<0.10) in these invasive cancer specimens. Contrary to recent studies p53 immunostaining was not correlated with disease-specific survival. Bcl-2 immunostaining was found in 28% of patients and was not correlated with grade (p>0.25) or disease-specific survival. No combination of p53 and Bcl-2 staining gave added predictive information. CONCLUSIONS: Cytoplasmic Bcl-2 is found in a small percentage of these cancers and does not correlate with prognosis. Further, p53 molecular overexpression is detected in the majority of muscle-invasive bladder tumors as a field defect. However, in patients undergoing cystectomy, it does not correlate with prognosis.
PURPOSE: We examined the presence of the p53 and Bcl-2 oncoproteins, as detected by immunohistochemistry, in muscle-invasive bladder cancer and correlated this with survival. MATERIALS AND METHODS:Formalin-fixed cystectomy specimens from 41 consecutive patients with mean follow-up of 52 months were used. Five patients were either lost to follow-up or died of other diseases and were not included in the survival evaluation. RESULTS: Eighteen of 36 patients died of metastatic transitional cell carcinoma. p53 immunostaining was found in 61% of patients. In 21 of 23 this staining was homogeneous, with more than 75% of cancer cells staining using a DO-1/DO-7 antibody cocktail. p53 staining was not correlated with stage (p>0.25) or grade (p<0.10) in these invasive cancer specimens. Contrary to recent studies p53 immunostaining was not correlated with disease-specific survival. Bcl-2 immunostaining was found in 28% of patients and was not correlated with grade (p>0.25) or disease-specific survival. No combination of p53 and Bcl-2 staining gave added predictive information. CONCLUSIONS: Cytoplasmic Bcl-2 is found in a small percentage of these cancers and does not correlate with prognosis. Further, p53 molecular overexpression is detected in the majority of muscle-invasive bladder tumors as a field defect. However, in patients undergoing cystectomy, it does not correlate with prognosis.
Authors: M A Ghanem; T H Van der Kwast; J C Den Hollander; M K Sudaryo; M M Van den Heuvel; M A Noordzij; R J Nijman; E H Soliman; G J van Steenbrugge Journal: Br J Cancer Date: 2001-11-16 Impact factor: 7.640
Authors: Jens Mani; Stefan Vallo; Stefanie Rakel; Patrick Antonietti; Florian Gessler; Roman Blaheta; Georg Bartsch; Martin Michaelis; Jindrich Cinatl; Axel Haferkamp; Donat Kögel Journal: BMC Cancer Date: 2015-04-07 Impact factor: 4.430
Authors: Doreen Kunze; Kai Kraemer; Kati Erdmann; Michael Froehner; Manfred P Wirth; Susanne Fuessel Journal: Int J Oncol Date: 2012-07-06 Impact factor: 5.650